Future directions in multiple myeloma treatment.

about

Future directions in multiple myeloma treatment.

Item

http://www.wikidata.org/entity/Q36258701

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Future directions in multiple myeloma treatment.

@ast

Future directions in multiple myeloma treatment.

@en

type

Item

label

Future directions in multiple myeloma treatment.

@ast

Future directions in multiple myeloma treatment.

@en

prefLabel

Future directions in multiple myeloma treatment.

@ast

Future directions in multiple myeloma treatment.

@en

P1476

Future directions in multiple myeloma treatment.

@en

P2093

J Anthony Child

http://www.w3.org/2001/XMLSchema#string

Nigel Russell

http://www.w3.org/2001/XMLSchema#string

Steve Schey

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

International staging system for multiple myeloma.

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

P304

8-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000087038

http://www.w3.org/2001/XMLSchema#string

P478

114 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Pieter Sonneveld

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16166766

http://www.w3.org/2001/XMLSchema#string